Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

BRENDA Home
show all | hide all No of entries

Information on EC 2.5.1.10 - (2E,6E)-farnesyl diphosphate synthase and Organism(s) Homo sapiens

for references in articles please use BRENDA:EC2.5.1.10
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
IUBMB Comments
Some forms of this enzyme will also use dimethylallyl diphosphate as a substrate. The enzyme will not accept larger prenyl diphosphates as efficient donors.
Specify your search results
Select one or more organisms in this record: ?
This record set is specific for:
Homo sapiens
Show additional data
Do not include text mining results
Include (text mining) results
Include results (AMENDA + additional results, but less precise)
Word Map
The taxonomic range for the selected organisms is: Homo sapiens
The enzyme appears in selected viruses and cellular organisms
Synonyms
farnesyl diphosphate synthase, farnesyl pyrophosphate synthase, fpp synthase, erg20, farnesyl pyrophosphate synthetase, hfpps, farnesyl-diphosphate synthase, fppase, fpps1, fpps3, more
SYNONYM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
farnesyl pyrophosphate synthase
farnesyl pyrophosphate synthetase
-
-
-
-
farnesyl-diphosphate synthase
-
-
-
-
farnesylpyrophosphate synthetase
-
-
-
-
geranyl transferase I
-
-
-
-
geranyltranstransferase
-
-
-
-
prenyltransferase
-
-
-
-
REACTION
REACTION DIAGRAM
COMMENTARY hide
ORGANISM
UNIPROT
LITERATURE
geranyl diphosphate + isopentenyl diphosphate = diphosphate + (2E,6E)-farnesyl diphosphate
show the reaction diagram
bimolecular nucleophilic substitution, SN2 reaction, proceeds with an inversion of configuration at the diphosphate-bearing carbon of the allylic substrate and removal of the pro-R hydrogen from the C-2 of isopentenyl diphosphate in these trans-polyprenol synthetic reactions
-
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
alkenyl group transfer
-
-
-
-
SYSTEMATIC NAME
IUBMB Comments
geranyl-diphosphate:isopentenyl-diphosphate geranyltranstransferase
Some forms of this enzyme will also use dimethylallyl diphosphate as a substrate. The enzyme will not accept larger prenyl diphosphates as efficient donors.
CAS REGISTRY NUMBER
COMMENTARY hide
37277-79-5
-
SUBSTRATE
PRODUCT                       
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
dimethylallyl diphosphate + 2 isopentenyl diphosphate
(E,E)-farnesyl diphosphate + 2 diphosphate
show the reaction diagram
-
2 sequential irreversible 1', 4 condensations
-
-
ir
dimethylallyl diphosphate + isopentenyl diphosphate
diphosphate + geranyl diphosphate
show the reaction diagram
geranyl diphosphate + isopentenyl diphosphate
diphosphate + (2E,6E)-farnesyl diphosphate
show the reaction diagram
geranyl diphosphate + isopentenyl diphosphate
diphosphate + farnesyl diphosphate
show the reaction diagram
-
-
-
ir
isopentenyl diphosphate + dimethylallyl diphosphate
diphosphate + geranyl diphosphate
show the reaction diagram
-
-
-
?
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate) hide
LITERATURE
(Substrate)
COMMENTARY
(Product) hide
LITERATURE
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
dimethylallyl diphosphate + isopentenyl diphosphate
diphosphate + geranyl diphosphate
show the reaction diagram
geranyl diphosphate + isopentenyl diphosphate
diphosphate + (2E,6E)-farnesyl diphosphate
show the reaction diagram
isopentenyl diphosphate + dimethylallyl diphosphate
diphosphate + geranyl diphosphate
show the reaction diagram
-
-
-
?
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
Mn2+
-
-
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
(((2-phenylthieno[2,3-d]pyrimidin-4-yl)amino)methylene)diphosphonic acid
-
about 75% inhibition at 0.01 mM
(((5-phenylthieno[2,3-d]pyrimidin-4-yl)amino)methylene)diphosphonic acid
-
about 10% inhibition at 0.01 mM
(((6-(4-tolyl)thieno[2,3-d]pyrimidin-4-yl)amino)methylene)diphosphonic acid
-
about 85% inhibition at 0.01 mM
(((6-(naphthalen-2-yl)thieno[2,3-d]pyrimidin-4-yl)amino)methylene)diphosphonic acid
-
about 87% inhibition at 0.01 mM
(4bR,8aS)-4b-(5-acetyl-1,3,4-oxadiazol-2-yl)-8,8-dimethyl-2-(propan-2-yl)-5,6,7,8,8a,9-hexahydrophenanthrene-3,4,10(4bH)-trione
-
(4bR,8aS)-4b-(5-amino-1,3,4-oxadiazol-2-yl)-8,8-dimethyl-2-(propan-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol
-
(4bR,8aS)-4b-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-8,8-dimethyl-2-(propan-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol
-
(4bR,8aS)-4b-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-8,8-dimethyl-2-(propan-2-yl)-5,6,7,8,8a,9-hexahydrophenanthrene-3,4,10(4bH)-trione
-
(4bR,8aS)-4b-(5-[(1S)-1-[(hydroxymethyl)amino]ethyl]-1,3,4-oxadiazol-2-yl)-8,8-dimethyl-2-(propan-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol
-
(4bR,8aS)-4b-[5-(4-bromophenyl)-1,3,4-oxadiazol-2-yl]-8,8-dimethyl-2-(propan-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol
-
(4bR,8aS)-4b-[5-(4-bromophenyl)-1,3,4-oxadiazol-2-yl]-8,8-dimethyl-2-(propan-2-yl)-5,6,7,8,8a,9-hexahydrophenanthrene-3,4,10(4bH)-trione
-
(4bR,8aS)-4b-[5-[(dimethylamino)methyl]-1,3,4-oxadiazol-2-yl]-8,8-dimethyl-2-(propan-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol
-
(6-phenylthieno[2,3-d]pyrimidin-4-ylamino)methylenebisphosphonic acid
-
about 61% inhibition at 0.01 mM
(R)-(1-((6-(3-chloro-4-methylphenyl)thieno[2,3-d]-pyrimidin-4-yl)amino)-2-(3-fluorophenyl)ethyl)phosphonic acid
-
(R)-(1-((6-(3-chloro-4-methylphenyl)thieno[2,3-d]-pyrimidin-4-yl)amino)-2-cyclohexylethyl)phosphonic acid
-
(R)-(1-((6-(3-chloro-4-methylphenyl)thieno[2,3-d]-pyrimidin-4-yl)amino)-2-phenylethyl)phosphonic acid
-
(R)-(2-(3-fluorophenyl)-1-((6-(p-tolyl)thieno[2,3-d]-pyrimidin-4-yl)amino)ethyl)phosphonic acid
-
(R)-(2-phenyl-1-((6-(p-tolyl)thieno[2,3-d]pyrimidin-4-yl)-amino)ethyl)phosphonic acid
-
(R)-2-((6-(3-chloro-4-methylphenyl)thieno[2,3-d]-pyrimidin-4-yl)amino)-3-(3-fluorophenyl)propanoic acid
-
(S)-(1-((6-(3-chloro-4-methylphenyl)thieno[2,3-d]-pyrimidin-4-yl)amino)-2-(3-fluorophenyl)ethyl)phosphonic acid
-
(S)-(1-((6-(3-chloro-4-methylphenyl)thieno[2,3-d]-pyrimidin-4-yl)amino)-2-cyclohexylethyl)phosphonic acid
-
(S)-(1-((6-(3-chloro-4-methylphenyl)thieno[2,3-d]-pyrimidin-4-yl)amino)-2-phenylethyl)phosphonic acid
-
(S)-(2-(3-fluorophenyl)-1-((6-(p-tolyl)thieno[2,3-d]-pyrimidin-4-yl)amino)ethyl)phosphonic acid
-
(S)-(2-phenyl-1-((6-(p-tolyl)thieno[2,3-d]pyrimidin-4-yl)-amino)ethyl)phosphonic acid
-
(thieno[2,3-d]pyrimidin-4-ylamino)methylene bisphosphonic acid
-
about 78% inhibition at 0.01 mM
([[6-(1-methyl-1H-pyrazol-4-yl)pyridin-3-yl]amino]methanediyl)bis(phosphonic acid)
-
([[6-(3-methoxyphenyl)pyridin-3-yl]amino]methanediyl)bis(phosphonic acid)
-
([[6-(4-methylphenyl)-5,6-dihydrothieno[2,3-d]pyrimidin-4-yl]amino]methyl)phosphonic acid
-
([[6-(thiophen-3-yl)pyridin-3-yl]amino]methanediyl)bis(phosphonic acid)
-
1-(carboxymethyl)-1H-benzo[g]indole-2-carboxylic acid
-
1-(carboxymethyl)-5,9b-dihydro-1H-benzo[g]indole-2-carboxylic acid
-
1-[(3-carboxy-1,2-oxazol-5-yl)methyl]-1H-benzo[g]indole-2-carboxylic acid
-
-
1-[(benzyloxy)carbonyl]-2,3-dihydro-1H-indole-2-carboxylic acid
-
-
11,12-dihydroxy-7,20-epoxyabieta-8,11,13-trien-20-one
-
11,12-dihydroxy-N-(2-hydroxyethyl)abieta-8(14),9(11),12-trien-20-amide
-
11,12-dihydroxy-N-methylabieta-8(14),9(11),12-trien-20-amide
-
11,12-dihydroxy-N-[(pyridin-3-yl)methyl]abieta-8(14),9(11),12-trien-20-amide
-
11,12-dihydroxy-N-[3-(1H-imidazol-1-yl)propyl]abieta-8(14),9(11),12-trien-20-amide
-
11,12-dihydroxyabieta-8(14),9(11),12-triene-20-hydrazide
-
11-hydroxyabieta-7,9(11),13-triene-6,12-dione
-
12-hydroxy-11,20-epoxyabieta-8(14),9(11),12-trien-20-one
-
1H,1'H-4,4'-biindole-2-carboxylic acid
-
-
2,6,7-trihydroxy-9-(2-hydroxyphenyl)-4,4a-dihydro-3H-xanthen-3-one
-
2-(naphthalen-1-ylmethoxy)-4-(phenylamino)benzoic acid
-
-
2-(naphthalen-1-ylmethoxy)benzoic acid
-
-
2-[11,12-dihydroxy-20-oxoabieta-8(14),9(11),12-trien-20-yl]hydrazine-1-carboxamide
-
2-[[(1S,2R,4aR)-4a-hydroxy-1,2-dimethyl-5-methylidenedecahydronaphthalen-1-yl]methyl]cyclohexa-2,5-diene-1,4-dione
-
3-(naphthalen-1-ylmethoxy)biphenyl-4-carboxylic acid
-
-
4'-(hydroxymethyl)-3-(naphthalen-1-ylmethoxy)biphenyl-4-carboxylic acid
-
-
4'-(methylcarbamoyl)-3-[(naphthalen-1-yl)methoxy][1,1'-biphenyl]-4-carboxylic acid
-
-
4'-acetamido-3-[(naphthalen-1-yl)methoxy][1,1'-biphenyl]-4-carboxylic acid
-
-
4'-carbamoyl-3-(naphthalen-1-ylmethoxy)biphenyl-4-carboxylic acid
-
-
4'-fluoro-3-(naphthalen-1-ylmethoxy)biphenyl-4-carboxylic acid
-
-
4'-[(methanesulfonyl)amino]-3-[(naphthalen-1-yl)methoxy][1,1'-biphenyl]-4-carboxylic acid
-
-
4-(1,3-benzodioxol-5-yl)-2-(naphthalen-1-ylmethoxy)benzoic acid
-
-
4-(1-methyl-1H-indol-5-yl)-2-[(naphthalen-1-yl)methoxy]benzoic acid
-
-
4-(1H-indol-5-yl)-2-(naphthalen-1-ylmethoxy)benzoic acid
-
-
4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[(naphthalen-1-yl)methoxy]benzoic acid
-
-
4-(6-methoxynaphthalen-2-yl)-2-[(naphthalen-1-yl)methoxy]benzoic acid
-
-
4-(naphthalen-1-yl)-1H-indole-2-carboxylic acid
-
-
4-[5-[(4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-(propan-2-yl)-1,3,4,9,10,10a-hexahydrophenanthren-4a(2H)-yl]-1,3,4-oxadiazol-2-yl]benzonitrile
-
6,20-epoxyabieta-8,13-diene-7,11,12,20-tetrone
-
6-amino-5-ethoxy-8-(naphthalen-1-yl)quinoline-2-carboxylic acid
-
-
6-amino-8-(naphthalen-1-yl)quinoline-2-carboxylic acid
-
-
6-[(ethoxycarbonyl)amino]-8-(naphthalen-1-yl)quinoline-2-carboxylic acid
-
-
7,20-epoxyabieta-8(14),9(11),12-triene-11,12-diol
-
7,20-epoxyabieta-8,13-diene-11,12,20-trione
-
7,20-epoxyabieta-8,13-diene-11,12-dione
-
8-(1H-indol-4-yl)quinoline-2-carboxylic acid
-
-
8-(naphthalen-1-yl)-6-(1H-pyrrol-2-yl)quinoline-2-carboxylic acid
-
-
8-(naphthalen-1-yl)-6-(thiophen-3-yl)quinoline-2-carboxylic acid
-
-
8-(naphthalen-1-yl)quinoline-2-carboxylic acid
-
-
abieta-8(14),9(11),12-triene-11,12,20-triol
-
alendronate
alendronic acid
-
arenarone
-
bisphosphonate
-
celastrol
-
clodronate
-
etidronate
-
farnesyl diphosphate
allosteric product inhibition. the product can trap the enzyme in an unreactive state by binding to its allosteric pocket
ibandronate
-
ibandronic acid
-
incadronate
-
isopentenyl diphosphate
-
-
methyl 11,12-dihydroxy-7-(phenylsulfanyl)abieta-8(14),9(11),12-trien-20-oate
-
methyl 11,12-dihydroxy-7-methoxyabieta-8(14),9(11),12-trien-20-oate
-
methyl 11,12-dihydroxy-7-oxoabieta-8(14),9(11),12-trien-20-oate
-
methyl 11,12-dihydroxy-7-[(2-hydroxyethyl)sulfanyl]abieta-8(14),9(11),12-trien-20-oate
-
methyl 11,12-dihydroxyabieta-7,9(11),13-trien-20-oate
-
methyl 11,12-dihydroxyabieta-8(14),9(11),12-trien-20-oate
-
methyl 11-[[tert-butyl(dimethyl)silyl]oxy]-12-hydroxyabieta-8(14),9(11),12-trien-20-oate
-
methyl 7,11,12-trioxoabieta-8,13-dien-20-oate
-
methyl 7-(butylsulfanyl)-11,12-dihydroxyabieta-8(14),9(11),12-trien-20-oate
-
methyl 7-ethoxy-11,12-dihydroxyabieta-8(14),9(11),12-trien-20-oate
-
methyl 7-ethoxy-11,12-dioxoabieta-8,13-dien-20-oate
-
methyl 7-tert-butoxy-11,12-dioxoabieta-8,13-dien-20-oate
-
methyl 7-[(2-hydroxyethyl)sulfanyl]-11,12-dioxoabieta-8,13-dien-20-oate
-
minodronic acid
-
N'-(4-bromobenzoyl)-11,12-dihydroxyabieta-8(14),9(11),12-triene-20-hydrazide
-
N'-acetyl-11,12-dihydroxyabieta-8(14),9(11),12-triene-20-hydrazide
-
N-acetyl-S-((4aR,10aS)-5,6-dihydroxy-7-isopropyl-4a-(methoxycarbonyl)-1,1-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-9-yl)-L-cysteine
-
N-benzyl-11,12-dihydroxyabieta-8(14),9(11),12-trien-20-amide
-
N-[2-(dimethylamino)ethyl]-11,12-dihydroxy-7-oxoabieta-8(14),9(11),12-trien-20-amide
-
N-[2-(dimethylamino)ethyl]-11,12-dihydroxyabieta-8(14),9(11),12-trien-20-amide
-
neridronate
-
pamidronate
pamidronic acid
-
Phenylglyoxal
-
-
Pyrophosphate
-
residronate
-
risedronate
risedronic acid
-
taxodione
-
tert-butyl [(1R)-1-amino-2-[2-[11,12-dihydroxy-20-oxoabieta-8(14),9(11),12-trien-20-yl]hydrazinyl]-2-oxoethyl]carbamate
-
tert-butyl [(1R)-1-[5-[(4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-9-oxo-7-(propan-2-yl)-1,3,4,9,10,10a-hexahydrophenanthren-4a(2H)-yl]-1,3,4-oxadiazol-2-yl]ethyl]carbamate
-
tert-butyl [(1S)-1-[5-[(4aR,10aS)-1,1-dimethyl-5,6,9-trioxo-7-(propan-2-yl)-1,3,4,5,6,9,10,10a-octahydrophenanthren-4a(2H)-yl]-1,3,4-oxadiazol-2-yl]ethyl]carbamate
-
tert-butyl [(1S)-1-[5-[(4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-(propan-2-yl)-1,3,4,9,10,10a-hexahydrophenanthren-4a(2H)-yl]-1,3,4-oxadiazol-2-yl]ethyl]carbamate
-
tiludronate
-
ZINC04011866
0.01 mM, 29.9% inhibition
ZINC04043066
0.01 mM, 25.3% inhibition
ZINC04064228
0.01 mM, 11.5% inhibition
ZINC04082083
0.01 mM, 17.3% inhibition
ZINC04763743
0.01 mM, 29.4% inhibition
ZINC05037497
0.01 mM, 29.3% inhibition
ZINC06894343
0.01 mM, 28.9% inhibition
ZINC09224949
0.01 mM, 23.5% inhibition
ZINC12377242
0.01 mM, 13% inhibition
ZINC15868804
0.01 mM, 24% inhibition
zoledronate
zoledronic acid
[([6-[3-(trifluoromethyl)phenyl]pyridin-3-yl]amino)methanediyl]bis(phosphonic acid)
-
[({4-[4-(propan-2-yloxy)phenyl]pyridin-2-yl}amino)methanediyl]bis(phosphonic acid)
-
about 90% inhibition at 0.01 mM
[1-fluoro-2-[2-(1H-indazol-4-yl)pyridin-4-yl]ethane-1,1-diyl]bis(phosphonic acid)
-
[1-fluoro-2-[5-(1H-indazol-4-yl)pyridin-2-yl]ethane-1,1-diyl]bis(phosphonic acid)
-
[1-fluoro-2-[5-(1H-indazol-4-yl)pyridin-3-yl]ethane-1,1-diyl]bis(phosphonic acid)
-
[1-fluoro-2-[5-(1H-indazol-5-yl)pyridin-2-yl]ethane-1,1-diyl]bis(phosphonic acid)
-
[1-fluoro-2-[5-(1H-indazol-5-yl)pyridin-3-yl]ethane-1,1-diyl]bis(phosphonic acid)
-
[1-fluoro-2-[5-(1H-indazol-6-yl)pyridin-3-yl]ethane-1,1-diyl]bis(phosphonic acid)
-
[1-fluoro-2-[5-(1H-pyrazol-4-yl)pyridin-2-yl]ethane-1,1-diyl]bis(phosphonic acid)
-
[1-fluoro-2-[5-(1H-pyrazol-4-yl)pyridin-3-yl]ethane-1,1-diyl]bis(phosphonic acid)
-
[1-fluoro-2-[6-(1H-pyrazol-4-yl)pyridin-3-yl]ethane-1,1-diyl]bis(phosphonic acid)
-
[2-(1,2-dimethyl-1H-indol-3-yl)ethane-1,1-diyl]bis(phosphonic acid)
about 64% inhibition at 0.01 mM
[2-(1-ethyl-1H-indol-3-yl)ethane-1,1-diyl]bis(phosphonic acid)
about 78% inhibition at 0.01 mM
[2-(1-methyl-1H-indol-3-yl)ethane-1,1-diyl]bis(phosphonic acid)
about 60% inhibition at 0.01 mM
[2-(2-methyl-1H-indol-3-yl)ethane-1,1-diyl]bis(phosphonic acid)
about 30% inhibition at 0.01 mM
[2-(2-tert-butyl-1H-indol-3-yl)ethane-1,1-diyl]bis(phosphonic acid)
about 79% inhibition at 0.01 mM
[2-[2-(3,5-dimethyl-1,2-oxazol-4-yl)pyridin-4-yl]-1-fluoroethane-1,1-diyl]bis(phosphonic acid)
-
[2-[5-(3,5-dimethyl-1,2-oxazol-4-yl)pyridin-3-yl]-1-fluoroethane-1,1-diyl]bis(phosphonic acid)
-
[2-[6-(3,5-dimethyl-1,2-oxazol-4-yl)pyridin-2-yl]-1-fluoroethane-1,1-diyl]bis(phosphonic acid)
-
[6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid)
i.e. NE-10501, chiral analog of risedronate. Crystallization of human enzyme from a solution of racemic NE-10501 results in a complex containing the R enantiomer in the enzyme active site
{2-[(1-methyl-1H-imidazo[4,5-b]pyridin-2-yl)amino]ethane-1,1-diyl}bis(phosphonic acid)
about 65% inhibition at 0.01 mM
{2-[(3-methyl-3H-imidazo[4,5-b]pyridin-2-yl)amino]ethane-1,1-diyl}bis(phosphonic acid)
about 10% inhibition at 0.01 mM
{2-[1-(propan-2-yl)-1H-indol-3-yl]ethane-1,1-diyl}bis(phosphonic acid)
about 45% inhibition at 0.01 mM
{2-[2-(1-cyclopentylethyl)-1H-indol-3-yl]ethane-1,1-diyl}bis(phosphonic acid)
about 90% inhibition at 0.01 mM
{2-[2-(3-methylbutan-2-yl)-1H-indol-3-yl]ethane-1,1-diyl}bis(phosphonic acid)
about 85% inhibition at 0.01 mM
{2-[2-(3-methylbutan-2-yl)-5-phenyl-1H-indol-3-yl]ethane-1,1-diyl}bis(phosphonic acid)
about 95% inhibition at 0.01 mM
additional information
-
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
dithioerythritol
-
-
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.00054
(R)-(1-((6-(3-chloro-4-methylphenyl)thieno[2,3-d]-pyrimidin-4-yl)amino)-2-(3-fluorophenyl)ethyl)phosphonic acid
pH 7.7, 37°C
0.003
(R)-(1-((6-(3-chloro-4-methylphenyl)thieno[2,3-d]-pyrimidin-4-yl)amino)-2-cyclohexylethyl)phosphonic acid
pH 7.7, 37°C
0.0015
(R)-(1-((6-(3-chloro-4-methylphenyl)thieno[2,3-d]-pyrimidin-4-yl)amino)-2-phenylethyl)phosphonic acid
pH 7.7, 37°C
0.0028
(R)-(2-(3-fluorophenyl)-1-((6-(p-tolyl)thieno[2,3-d]-pyrimidin-4-yl)amino)ethyl)phosphonic acid
pH 7.7, 37°C
0.0077
(R)-(2-phenyl-1-((6-(p-tolyl)thieno[2,3-d]pyrimidin-4-yl)-amino)ethyl)phosphonic acid
pH 7.7, 37°C
0.001
(R)-2-((6-(3-chloro-4-methylphenyl)thieno[2,3-d]-pyrimidin-4-yl)amino)-3-(3-fluorophenyl)propanoic acid
pH 7.7, 37°C
0.0011
(S)-(1-((6-(3-chloro-4-methylphenyl)thieno[2,3-d]-pyrimidin-4-yl)amino)-2-(3-fluorophenyl)ethyl)phosphonic acid
pH 7.7, 37°C
0.0081
(S)-(1-((6-(3-chloro-4-methylphenyl)thieno[2,3-d]-pyrimidin-4-yl)amino)-2-cyclohexylethyl)phosphonic acid
pH 7.7, 37°C
0.0037
(S)-(1-((6-(3-chloro-4-methylphenyl)thieno[2,3-d]-pyrimidin-4-yl)amino)-2-phenylethyl)phosphonic acid
pH 7.7, 37°C
0.0012
(S)-(2-(3-fluorophenyl)-1-((6-(p-tolyl)thieno[2,3-d]-pyrimidin-4-yl)amino)ethyl)phosphonic acid
pH 7.7, 37°C
0.0028
(S)-(2-phenyl-1-((6-(p-tolyl)thieno[2,3-d]pyrimidin-4-yl)-amino)ethyl)phosphonic acid
pH 7.7, 37°C
0.00026
alendronate
pH and temperature not specified in the publication
0.00298
APHBP
pH and temperature not specified in the publication
0.0007
isopentenyl diphosphate
-
-
0.000388
neridronate
pH and temperature not specified in the publication
0.000352
pamidronate
pH and temperature not specified in the publication
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
IMAGE
0.000289
(4bR,8aS)-4b-(5-acetyl-1,3,4-oxadiazol-2-yl)-8,8-dimethyl-2-(propan-2-yl)-5,6,7,8,8a,9-hexahydrophenanthrene-3,4,10(4bH)-trione
Homo sapiens
pH 7.5, 23°C
0.000859
(4bR,8aS)-4b-(5-amino-1,3,4-oxadiazol-2-yl)-8,8-dimethyl-2-(propan-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol
Homo sapiens
pH 7.5, 23°C
0.0022
(4bR,8aS)-4b-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-8,8-dimethyl-2-(propan-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol
Homo sapiens
pH 7.5, 23°C
0.000335
(4bR,8aS)-4b-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-8,8-dimethyl-2-(propan-2-yl)-5,6,7,8,8a,9-hexahydrophenanthrene-3,4,10(4bH)-trione
Homo sapiens
pH 7.5, 23°C
0.000194
(4bR,8aS)-4b-(5-[(1S)-1-[(hydroxymethyl)amino]ethyl]-1,3,4-oxadiazol-2-yl)-8,8-dimethyl-2-(propan-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol
Homo sapiens
pH 7.5, 23°C
0.0251
(4bR,8aS)-4b-[5-(4-bromophenyl)-1,3,4-oxadiazol-2-yl]-8,8-dimethyl-2-(propan-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol
Homo sapiens
pH 7.5, 23°C
0.0137
(4bR,8aS)-4b-[5-(4-bromophenyl)-1,3,4-oxadiazol-2-yl]-8,8-dimethyl-2-(propan-2-yl)-5,6,7,8,8a,9-hexahydrophenanthrene-3,4,10(4bH)-trione
Homo sapiens
pH 7.5, 23°C
0.0011
(4bR,8aS)-4b-[5-[(dimethylamino)methyl]-1,3,4-oxadiazol-2-yl]-8,8-dimethyl-2-(propan-2-yl)-4b,5,6,7,8,8a,9,10-octahydrophenanthrene-3,4-diol
Homo sapiens
pH 7.5, 23°C
0.081
1-(carboxymethyl)-1H-benzo[g]indole-2-carboxylic acid
Homo sapiens
pH and temperature not specified in the publication
0.0133
11,12-dihydroxy-7,20-epoxyabieta-8,11,13-trien-20-one
Homo sapiens
pH 7.5, 23°C
0.000914
11,12-dihydroxy-N-(2-hydroxyethyl)abieta-8(14),9(11),12-trien-20-amide
Homo sapiens
pH 7.5, 23°C
0.0027
11,12-dihydroxy-N-methylabieta-8(14),9(11),12-trien-20-amide
Homo sapiens
pH 7.5, 23°C
0.0027
11,12-dihydroxy-N-[(pyridin-3-yl)methyl]abieta-8(14),9(11),12-trien-20-amide
Homo sapiens
pH 7.5, 23°C
0.008
11,12-dihydroxy-N-[3-(1H-imidazol-1-yl)propyl]abieta-8(14),9(11),12-trien-20-amide
Homo sapiens
pH 7.5, 23°C
0.035
11,12-dihydroxyabieta-8(14),9(11),12-triene-20-hydrazide
Homo sapiens
pH 7.5, 23°C
0.0012 - 0.0024
11-hydroxyabieta-7,9(11),13-triene-6,12-dione
0.0106
12-hydroxy-11,20-epoxyabieta-8(14),9(11),12-trien-20-one
Homo sapiens
pH 7.5, 23°C
0.0139
1H,1'H-4,4'-biindole-2-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.081
2,6,7-trihydroxy-9-(2-hydroxyphenyl)-4,4a-dihydro-3H-xanthen-3-one
Homo sapiens
pH and temperature not specified in the publication
0.02
2-(naphthalen-1-ylmethoxy)-4-(phenylamino)benzoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.0068
2-(naphthalen-1-ylmethoxy)benzoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.0031
2-[11,12-dihydroxy-20-oxoabieta-8(14),9(11),12-trien-20-yl]hydrazine-1-carboxamide
Homo sapiens
pH 7.5, 23°C
0.0011
2-[[(1S,2R,4aR)-4a-hydroxy-1,2-dimethyl-5-methylidenedecahydronaphthalen-1-yl]methyl]cyclohexa-2,5-diene-1,4-dione
Homo sapiens
pH and temperature not specified in the publication
0.00085
3-(naphthalen-1-ylmethoxy)biphenyl-4-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.000058
4'-(hydroxymethyl)-3-(naphthalen-1-ylmethoxy)biphenyl-4-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.00014
4'-(methylcarbamoyl)-3-[(naphthalen-1-yl)methoxy][1,1'-biphenyl]-4-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.000017
4'-acetamido-3-[(naphthalen-1-yl)methoxy][1,1'-biphenyl]-4-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.00011
4'-carbamoyl-3-(naphthalen-1-ylmethoxy)biphenyl-4-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.00008
4'-fluoro-3-(naphthalen-1-ylmethoxy)biphenyl-4-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.00123
4'-[(methanesulfonyl)amino]-3-[(naphthalen-1-yl)methoxy][1,1'-biphenyl]-4-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.000049
4-(1,3-benzodioxol-5-yl)-2-(naphthalen-1-ylmethoxy)benzoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.00027
4-(1-methyl-1H-indol-5-yl)-2-[(naphthalen-1-yl)methoxy]benzoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.00019
4-(1H-indol-5-yl)-2-(naphthalen-1-ylmethoxy)benzoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.00025
4-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-[(naphthalen-1-yl)methoxy]benzoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.000038
4-(6-methoxynaphthalen-2-yl)-2-[(naphthalen-1-yl)methoxy]benzoic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.0071
4-(naphthalen-1-yl)-1H-indole-2-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.0074
4-[5-[(4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-(propan-2-yl)-1,3,4,9,10,10a-hexahydrophenanthren-4a(2H)-yl]-1,3,4-oxadiazol-2-yl]benzonitrile
Homo sapiens
pH 7.5, 23°C
0.000389
6,20-epoxyabieta-8,13-diene-7,11,12,20-tetrone
Homo sapiens
pH 7.5, 23°C
0.000024
6-amino-5-ethoxy-8-(naphthalen-1-yl)quinoline-2-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.000069
6-amino-8-(naphthalen-1-yl)quinoline-2-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.000037
6-[(ethoxycarbonyl)amino]-8-(naphthalen-1-yl)quinoline-2-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.0187
7,20-epoxyabieta-8(14),9(11),12-triene-11,12-diol
Homo sapiens
pH 7.5, 23°C
0.000473
7,20-epoxyabieta-8,13-diene-11,12,20-trione
Homo sapiens
pH 7.5, 23°C
0.000596
7,20-epoxyabieta-8,13-diene-11,12-dione
Homo sapiens
pH 7.5, 23°C
0.02
8-(1H-indol-4-yl)quinoline-2-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.000077
8-(naphthalen-1-yl)-6-(1H-pyrrol-2-yl)quinoline-2-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.0001
8-(naphthalen-1-yl)-6-(thiophen-3-yl)quinoline-2-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.0012
8-(naphthalen-1-yl)quinoline-2-carboxylic acid
Homo sapiens
-
pH and temperature not specified in the publication
0.0078
abieta-8(14),9(11),12-triene-11,12,20-triol
Homo sapiens
pH 7.5, 23°C
0.0011
arenarone
Homo sapiens
pH and temperature not specified in the publication
0.2
celastrol
Homo sapiens
IC50 above 0.2 mM, pH and temperature not specified in the publication
0.028
methyl 11,12-dihydroxy-7-(phenylsulfanyl)abieta-8(14),9(11),12-trien-20-oate
Homo sapiens
pH 7.5, 23°C
0.0011
methyl 11,12-dihydroxy-7-methoxyabieta-8(14),9(11),12-trien-20-oate
Homo sapiens
pH 7.5, 23°C
0.0412
methyl 11,12-dihydroxy-7-oxoabieta-8(14),9(11),12-trien-20-oate
Homo sapiens
pH 7.5, 23°C
0.0013
methyl 11,12-dihydroxy-7-[(2-hydroxyethyl)sulfanyl]abieta-8(14),9(11),12-trien-20-oate
Homo sapiens
pH 7.5, 23°C
0.000833
methyl 11,12-dihydroxyabieta-7,9(11),13-trien-20-oate
Homo sapiens
pH 7.5, 23°C
0.000865
methyl 11,12-dihydroxyabieta-8(14),9(11),12-trien-20-oate
Homo sapiens
pH 7.5, 23°C
0.0563
methyl 11-[[tert-butyl(dimethyl)silyl]oxy]-12-hydroxyabieta-8(14),9(11),12-trien-20-oate
Homo sapiens
pH 7.5, 23°C
0.000523
methyl 7,11,12-trioxoabieta-8,13-dien-20-oate
Homo sapiens
pH 7.5, 23°C
0.0125
methyl 7-(butylsulfanyl)-11,12-dihydroxyabieta-8(14),9(11),12-trien-20-oate
Homo sapiens
pH 7.5, 23°C
0.0133
methyl 7-ethoxy-11,12-dihydroxyabieta-8(14),9(11),12-trien-20-oate
Homo sapiens
pH 7.5, 23°C
0.0086
methyl 7-ethoxy-11,12-dioxoabieta-8,13-dien-20-oate
Homo sapiens
pH 7.5, 23°C
0.000234
methyl 7-tert-butoxy-11,12-dioxoabieta-8,13-dien-20-oate
Homo sapiens
pH 7.5, 23°C
0.0227
methyl 7-[(2-hydroxyethyl)sulfanyl]-11,12-dioxoabieta-8,13-dien-20-oate
Homo sapiens
pH 7.5, 23°C
0.0008
N'-(4-bromobenzoyl)-11,12-dihydroxyabieta-8(14),9(11),12-triene-20-hydrazide
Homo sapiens
pH 7.5, 23°C
0.0015
N'-acetyl-11,12-dihydroxyabieta-8(14),9(11),12-triene-20-hydrazide
Homo sapiens
pH 7.5, 23°C
0.02564
N-acetyl-S-((4aR,10aS)-5,6-dihydroxy-7-isopropyl-4a-(methoxycarbonyl)-1,1-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthren-9-yl)-L-cysteine
Homo sapiens
pH 7.5, 23°C
0.00603
N-benzyl-11,12-dihydroxyabieta-8(14),9(11),12-trien-20-amide
Homo sapiens
pH 7.5, 23°C
0.008
N-[2-(dimethylamino)ethyl]-11,12-dihydroxy-7-oxoabieta-8(14),9(11),12-trien-20-amide
Homo sapiens
pH 7.5, 23°C
0.0012
N-[2-(dimethylamino)ethyl]-11,12-dihydroxyabieta-8(14),9(11),12-trien-20-amide
Homo sapiens
pH 7.5, 23°C
0.0012
taxodione
Homo sapiens
pH and temperature not specified in the publication
0.0024
taxodone
Homo sapiens
pH and temperature not specified in the publication
0.00052
tert-butyl [(1R)-1-amino-2-[2-[11,12-dihydroxy-20-oxoabieta-8(14),9(11),12-trien-20-yl]hydrazinyl]-2-oxoethyl]carbamate
Homo sapiens
pH 7.5, 23°C
0.0125
tert-butyl [(1R)-1-[5-[(4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-9-oxo-7-(propan-2-yl)-1,3,4,9,10,10a-hexahydrophenanthren-4a(2H)-yl]-1,3,4-oxadiazol-2-yl]ethyl]carbamate
Homo sapiens
pH 7.5, 23°C
0.000252
tert-butyl [(1S)-1-[5-[(4aR,10aS)-1,1-dimethyl-5,6,9-trioxo-7-(propan-2-yl)-1,3,4,5,6,9,10,10a-octahydrophenanthren-4a(2H)-yl]-1,3,4-oxadiazol-2-yl]ethyl]carbamate
Homo sapiens
pH 7.5, 23°C
0.000644
tert-butyl [(1S)-1-[5-[(4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-(propan-2-yl)-1,3,4,9,10,10a-hexahydrophenanthren-4a(2H)-yl]-1,3,4-oxadiazol-2-yl]ethyl]carbamate
Homo sapiens
pH 7.5, 23°C
0.0001
zoledronate
Homo sapiens
pH 7.5, 23°C
0.0006295
[6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid)
Homo sapiens
racemat
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
0.922
-
-
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
7.3 - 8.8
-
-
7.5
assay at
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
23
assay at
37
-
assay at
ORGANISM
COMMENTARY hide
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
SOURCE
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY hide
GeneOntology No.
LITERATURE
SOURCE
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
drug target
malfunction
the blockade of farnesyl pyrophosphate synthase prevents the synthesis of farnesyl diphosphate and the downstream essential products
metabolism
physiological function
-
shRNA-mediated knock-down of expression results in conversion of hematopoietic and nonhematopoietic tumor cell lines into Vgamma9Vdelta2 T-cell activators. Knock-down cells activate Vgamma9Vdelta2 cells. Vgamma9Vdelta2 cells act as sensors of a dysregulated isoprenoid metabolism, therapeutic down-modulation of FPPS expression may be used as a tool to target tumor cells to Vgamma9Vdelta2 T-cell mediated immunosurveillance
UNIPROT
ENTRY NAME
ORGANISM
NO. OF AA
NO. OF TRANSM. HELICES
MOLECULAR WEIGHT[Da]
SOURCE
SEQUENCE
LOCALIZATION PREDICTION?
GGPPS_HUMAN
300
0
34871
Swiss-Prot
other Location (Reliability: 2)
FPPS_HUMAN
419
0
48275
Swiss-Prot
Mitochondrion (Reliability: 2)
PDB
SCOP
CATH
UNIPROT
ORGANISM
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
39000
-
x * 39000, SDS-PAGE
74000
-
gel filtration
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
?
-
x * 39000, SDS-PAGE
CRYSTALLIZATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
crystallization of human enzyme from a solution of racemic [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) results in a complex containing the R enantiomer in the enzyme active site. Contrary to known complexes of enzyme with risedronate, zoledronate, and minodronate, the complex with [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) displays only one Mg2+ ion
hanging drop vapor diffusion method, using 1.2 M phosphate buffer (pH 5.0), 25% (v/v) glycerol
in complex with chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid), i.e. NE-10501. The complex contains the R enantiomer in the enzymic active site, which is confirmed by docking studies. Presence of one Mg2+
vapor diffusion in sitting drops. In order to examine the actual binding interactions between the new PNP-BPs and hFPPS, co-crystal structures with the key inhibitors YS05035, JDS05119, and JDS05120 are determined
vapour diffusion in a sitting drop at 22°C. Crystalized in the presence of farnesyl diphosphate, and its X-ray structure is determined at 1.9 A resolution
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
thiol reducing agents are detrimental for stability
-
STORAGE STABILITY
ORGANISM
UNIPROT
LITERATURE
4°C, precipitate in neutral (NH4)2SO4 solution at 60% saturation, 1 year, 50-70% loss of activity
-
PURIFICATION (Commentary)
ORGANISM
UNIPROT
LITERATURE
partial purification
CLONED (Commentary)
ORGANISM
UNIPROT
LITERATURE
expressed in Escherichia coli
the enzyme with an N-terminal His6 tag is transformed into Escherichia coli BL21 (DE3) cells
APPLICATION
ORGANISM
UNIPROT
COMMENTARY hide
LITERATURE
medicine
-
shRNA-mediated knock-down of expression results in conversion of hematopoietic and nonhematopoietic tumor cell lines into Vgamma9Vdelta2 T-cell activators. Knock-down cells activate Vgamma9Vdelta2 cells. Vgamma9Vdelta2 cells act as sensors of a dysregulated isoprenoid metabolism, therapeutic down-modulation of FPPS expression may be used as a tool to target tumor cells to Vgamma9Vdelta2 T-cell mediated immunosurveillance
REF.
AUTHORS
TITLE
JOURNAL
VOL.
PAGES
YEAR
ORGANISM (UNIPROT)
PUBMED ID
SOURCE
Barnard, G.F.
Prenyltransferase from human liver
Methods Enzymol.
110
155-171
1985
Homo sapiens
Manually annotated by BRENDA team
Deprele, S.; Kashemirov, B.A.; Hogan,J.M.; Ebetino, F.H.; Barnett, B.L.; Evdokimov, A.; McKenna, C.E.
Farnesyl pyrophosphate synthase enantiospecificity with a chiral risedronate analog, [6,7-dihydro-5H-cyclopenta[c]pyridin-7-yl(hydroxy)methylene]bis(phosphonic acid) (NE-10501): Synthetic, structural, and modeling studies
Bioorg. Med. Chem. Lett.
18
2878-2882
2008
Homo sapiens (P14324), Homo sapiens
Manually annotated by BRENDA team
Li, J.; Herold, M.J.; Kimmel, B.; Mueller, I.; Rincon-Orozco, B.; Kunzmann, V.; Herrmann, T.
Reduced expression of the mevalonate pathway enzyme farnesyl pyrophosphate synthase unveils recognition of tumor cells by Vgamma9Vdelta2 T cells
J. Immunol.
182
8118-8124
2009
Homo sapiens
Manually annotated by BRENDA team
De Schutter, J.; Zaretsky, S.; Welbourn, S.; Pause, A.; Tsantrizos, Y.
Novel bisphosphonate inhibitors of the human farnesyl pyrophosphate synthase
Bioorg. Med. Chem. Lett.
20
5781-5786
2010
Homo sapiens (P14324), Homo sapiens
Manually annotated by BRENDA team
Das, S.; Edwards, P.A.; Crockett, J.C.; Rogers, M.J.
Upregulation of endogenous farnesyl diphosphate synthase overcomes the inhibitory effect of bisphosphonate on protein prenylation in Hela cells
Biochim. Biophys. Acta
1841
569-573
2014
Homo sapiens
Manually annotated by BRENDA team
Gritzalis, D.; Park, J.; Chiu, W.; Cho, H.; Lin, Y.S.; De Schutter, J.W.; Lacbay, C.M.; Zielinski, M.; Berghuis, A.M.; Tsantrizos, Y.S.
Probing the molecular and structural elements of ligands binding to the active site versus an allosteric pocket of the human farnesyl pyrophosphate synthase
Bioorg. Med. Chem. Lett.
25
1117-1123
2015
Homo sapiens (P14324), Homo sapiens
Manually annotated by BRENDA team
Leung, C.Y.; Langille, A.M.; Mancuso, J.; Tsantrizos, Y.S.
Discovery of thienopyrimidine-based inhibitors of the human farnesyl pyrophosphate synthase - parallel synthesis of analogs via a trimethylsilyl ylidene intermediate
Bioorg. Med. Chem.
21
2229-2240
2013
Homo sapiens
Manually annotated by BRENDA team
Marzinzik, A.L.; Amstutz, R.; Bold, G.; Bourgier, E.; Cotesta, S.; Glickman, J.F.; Goette, M.; Henry, C.; Lehmann, S.; Hartwieg, J.C.; Ofner, S.; Pelle, X.; Roddy, T.P.; Rondeau, J.M.; Stauffer, F.; Stout, S.J.; Widmer, A.; Zimmermann, J.; Zoller, T.; Jahnke, W.
Discovery of novel allosteric non-bisphosphonate inhibitors of farnesyl pyrophosphate synthase by integrated lead finding
ChemMedChem
10
1884-1891
2015
Homo sapiens
Manually annotated by BRENDA team
Liu, Y.L.; Lindert, S.; Zhu, W.; Wang, K.; McCammon, J.A.; Oldfield, E.
Taxodione and arenarone inhibit farnesyl diphosphate synthase by binding to the isopentenyl diphosphate site
Proc. Natl. Acad. Sci. USA
111
E2530-E2539
2014
Trypanosoma brucei, Homo sapiens (P14324), Homo sapiens
Manually annotated by BRENDA team
Kumar, P.; Kumar, A.; Sindhu, J.; Lal, S.
QSAR models for nitrogen containing monophosphonate and bisphosphonate derivatives as human farnesyl pyrophosphate synthase inhibitors based on Monte Carlo method
Drug Res.
69
159-167
2019
Homo sapiens (P14324), Homo sapiens
Manually annotated by BRENDA team
Liu, Q.; Miao, Y.; Wang, X.; Lv, G.; Peng, Y.; Li, K.; Li, M.; Qiu, L.; Lin, J.
Structure-based virtual screening and biological evaluation of novel non-bisphosphonate farnesyl pyrophosphate synthase inhibitors
Eur. J. Med. Chem.
186
111905
2020
Homo sapiens (P14324)
Manually annotated by BRENDA team
Rodriguez, J.B.; Falcone, B.N.; Szajnman, S.H.
Approaches for designing new potent inhibitors of farnesyl pyrophosphate synthase
Expert Opin. Drug Discov.
11
307-320
2016
Homo sapiens (P14324), Homo sapiens
Manually annotated by BRENDA team
Fernandez, D.; Ramis, R.; Ortega-Castro, J.; Casasnovas, R.; Vilanova, B.; Frau, J.
New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs
J. Comput. Aided Mol. Des.
31
675-688
2017
Homo sapiens (P14324), Homo sapiens
Manually annotated by BRENDA team
Han, S.; Li, X.; Xia, Y.; Yu, Z.; Cai, N.; Malwal, S.R.; Han, X.; Oldfield, E.; Zhang, Y.
Farnesyl pyrophosphate synthase as a target for drug development discovery of natural-product-derived inhibitors and their activity in pancreatic cancer cells
J. Med. Chem.
62
10867-10896
2019
Homo sapiens (P14324), Homo sapiens
Manually annotated by BRENDA team
Feng, Y.; Park, J.; Li, S.G.; Boutin, R.; Viereck, P.; Schilling, M.A.; Berghuis, A.M.; Tsantrizos, Y.S.
Chirality-driven mode of binding of alpha-aminophosphonic acid-based allosteric inhibitors of the human farnesyl pyrophosphate synthase (hFPPS)
J. Med. Chem.
62
9691-9702
2019
Homo sapiens (P14324), Homo sapiens
Manually annotated by BRENDA team
Park, J.; Zielinski, M.; Magder, A.; Tsantrizos, Y.S.; Berghuis, A.M.
Human farnesyl pyrophosphate synthase is allosterically inhibited by its own product
Nat. Commun.
8
14132
2017
Homo sapiens (P14324), Homo sapiens
Manually annotated by BRENDA team
Park, J.; Rodionov, D.; De Schutter, J.W.; Lin, Y.S.; Tsantrizos, Y.S.; Berghuis, A.M.
Crystallographic and thermodynamic characterization of phenylaminopyridine bisphosphonates binding to human farnesyl pyrophosphate synthase
PLoS ONE
12
e0186447
2017
Homo sapiens (P14324), Homo sapiens
Manually annotated by BRENDA team